NRXS neuraxis.com: Year-over-year net earnings per share growth for the last 12 months
NeurAxis, Inc. (NRXS) leads the non-surgical treatment of pediatric gastrointestinal disorders following FDA approval. However, challenges regarding physician training and patents are creating temporary headwinds. This quarterly earnings per share chart visualizes this balance, where -120.30 represents the current metric level. Long-term growth is supported by the expansion of insurance reimbursements, which creates a barrier to entry for new market participants.
NeurAxis, Inc. (NRXS) - metric breakdowns and financial figures
- share price and expert price forecast:
- company stock capitalization data:
- book capitalization indicators:
- debt and solvency information:
Total Debt to Equity Ratio NeurAxis, Inc.|NRXS - Long-Term Debt to Capital Coefficient|Short-Term Debt to Capital NeurAxis Inc.|NRXS - Company Total Debt Obligations|Debt to Book Capitalization Ratio NeurAxis Inc.|NRXS - Company Long-Term Indebtedness|Company Short-Term Debts NeurAxis|Quick Liquidity Indicator neuraxis.com
- earnings and valuation multiples indicators:
NRXS - Net Financial Result|Expected Profit NeurAxis, Inc.|NRXS - Price to Earnings Multiple|Future Price to Earnings NeurAxis, Inc.|NRXS - Growth-Adjusted Payback Ratio|Enterprise Value to EBITDA Ratio NeurAxis Inc.|NRXS - Operating profit before amortization|Earnings per share for the last twelve months NeurAxis|NRXS - Net earnings per share for the last four quarters|Year-over-year earnings per share growth for the last twelve months neuraxis.com|NRXS - Earnings per share growth this year|Earnings growth forecast for next year NeurAxis, Inc.
- sales and revenue data:
Analysis of all company metrics:NeurAxis, Inc.
This indicator measures the dynamics of net earnings per share, stripping the fundamental trend of short-term market noise and price volatility. For NeurAxis, Inc. (NRXS), whose neurotechnologies are protected by humanitarian status and stable supplies, the quarterly EPS growth rate serves as a marker of real business efficiency, where sustainable growth confirms the capitalization of its technological advantage.
Key competitors
BIIB: Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months Neurocrine Biosciences Inc (NBIX)|RGC (Regencell Bioscience Ltd) - Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months Axsome Therapeutics, Inc. AXSM|Year-over-year net earnings per share growth for the last 12 months ACAD (ACADIA Pharmaceuticals Inc.)|XENE: Year-over-year net earnings per share trend for the last twelve months|Viking Therapeutics, Inc. - Year-over-year net earnings per share growth for the last 12 months|Year-over-year net earnings per share change for the last twelve months Supernus Pharmaceuticals (SUPN)|CPRX: Year-over-year net earnings per share growth for the last 12 months|Year-over-year earnings per one share growth for the last 12 months DNLI (Denali Therapeutics)|HRMY: Quarterly EPS earnings growth|BHVN (Biohaven Pharmaceutical) - Year-over-year earnings per share growth for the last twelve months|Year-over-year earnings per share growth for the last twelve months Amylyx|Quarterly EPS earnings growth Trevi Corp|Quarterly EPS earnings growth PRAX|AVXL (anavex.com) - Year-over-year earnings per one share growth for the last 12 months|CeriBell Inc - Year-over-year net earnings per share growth for the last 12 months|PRTA (Prothena Corporation plc) - Year-over-year net earnings per share trend for the last twelve months|ALEC - Year-over-year earnings per share growth for the last twelve months|ANNX (Annexon Biosciences Inc.) - Year-over-year earnings per share growth for the last 12 months|OMER (omeros.com) - Year-over-year net earnings per share growth for the last 12 months|Year-over-year earnings per share growth for the last 12 months NGNE|Year-over-year net earnings per share growth for the last 12 months ACIU|Quarterly EPS earnings growth Voyager Pharma|Year-over-year net earnings per share growth for the last 12 months NMRA (Neumora Therapeutics, Inc.)|SCLX - Earnings per share growth in annualized terms for the last twelve months|Year-over-year earnings per share growth for the last twelve months Tevogen Bio TVGN|Alpha Cognition Corp (ACOG) - Earnings per share growth in annualized terms for the last twelve months|CGTX: Year-over-year net earnings per share growth for the last 12 months|Inhibikase Therapeutics, Inc. - Year-over-year earnings per share growth rate for the last twelve months|SAVA: Quarterly EPS earnings growth|Year-over-year earnings per share growth for the last 12 months ASRT|COYA (coyatherapeutics.com) - Quarterly EPS earnings growth|Vistagen (VTGN) - Year-over-year net earnings per share change for the last twelve months|Year-over-year net earnings per share growth for the last 12 months OVID (Ovid Rx)|Year-over-year net earnings per share change for the last twelve months Acumen Pharmaceuticals, Inc.|Quarterly EPS earnings growth CRVO (CervoMed Corporation)|Year-over-year earnings per share growth rate for the last twelve months ATHE (Alterity Therapeutics Ltd)|Clene Nanomedicine - Quarterly EPS earnings growth|Net earnings per share growth for the trailing year pepgen.com (PEPG)|JUNS: Quarterly EPS earnings growth|Year-over-year earnings per share growth for the last 12 months RLMD|ANVS (Annovis Bio Inc) - Quarterly EPS earnings growth|Year-over-year net earnings per share growth for the last 12 months Grace Therapeutics, Inc. (GRCE)|Quarterly EPS earnings growth AIFF|Year-over-year earnings per share growth rate for the last twelve months KLTO|Year-over-year earnings per share growth for the last twelve months neurosense-tx.com NRSN|Reviva Pharmaceuticals Holdings (RVPH) - Earnings per share growth in annualized terms for the last twelve months|MetaVia Inc. - Quarterly EPS earnings growth|Year-over-year net earnings per share change for the last twelve months Helius Medical Technologies, Inc. HSDT|PASG: Quarterly EPS earnings growth|Neuphoria (NEUP) - Quarterly EPS earnings growth|Year-over-year earnings per share growth for the last twelve months Minerva Neurosciences Inc|Athira Pharma Inc (ATHA) - Year-over-year net earnings per share change for the last twelve months|Year-over-year net earnings per share growth for the last 12 months ADXN (Addex Therapeutics)|Quarterly EPS earnings growth Alzamend Neuro Inc. (ALZN)|Cyclerion Therapeutics, Inc. - Year-over-year net earnings per share growth for the last 12 months|PTIX (Protagenic Therapeutics) - Year-over-year net earnings per share trend for the last twelve months|Pasithea Therapeutics Corp - Quarterly EPS earnings growth|Year-over-year net earnings per share change for the last twelve months Cortigent CRGT|ATXI (Avenue Therapeutics, Inc) - Year-over-year net earnings per share growth for the last 12 months|Brainstorm Cell Therapeutics, Inc. - Year-over-year earnings per one share growth for the last 12 months|Year-over-year net earnings per share growth for the last 12 months CARA|Earnings per share growth in annualized terms for the last twelve months chromocell.com CHRO|Year-over-year earnings per share growth for the last twelve months Eliem Therapeutics, Inc. (ELYM)|ITCI (Intra-Cellular Therapies, Inc.) - Year-over-year earnings per one share growth for the last 12 months|Quarterly EPS earnings growth LBPH (Longboard Pharmaceuticals Inc)|Quarterly EPS earnings growth Marinus Pharma MRNS|nkgenbiotech.com - Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months NeuroBo Pharmaceuticals, Inc.|Sage Therapeutics (SAGE) - Year-over-year earnings per share growth for the last twelve months|SNPX - Year-over-year net earnings per share change for the last twelve months|Year-over-year earnings per share growth for the last twelve months Trevena, Inc|Vigil Neuroscience (VIGL) - Year-over-year net earnings per share change for the last twelve months|Quarterly EPS earnings growth WENA|Quarterly EPS earnings growth cerevel.com (CERE)
